BMRN vs. SRPT, MYOK, TEVA, RETA, MRTX, BIIB, ALNY, NBIX, INCY, and UTHR
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Sarepta Therapeutics (SRPT), MyoKardia (MYOK), Teva Pharmaceutical Industries (TEVA), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
BioMarin Pharmaceutical (NASDAQ:BMRN) and Sarepta Therapeutics (NASDAQ:SRPT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
BioMarin Pharmaceutical currently has a consensus target price of $106.11, suggesting a potential upside of 41.34%. Sarepta Therapeutics has a consensus target price of $164.00, suggesting a potential upside of 26.29%. Given BioMarin Pharmaceutical's higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Sarepta Therapeutics.
98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
BioMarin Pharmaceutical has higher revenue and earnings than Sarepta Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioMarin Pharmaceutical has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
In the previous week, Sarepta Therapeutics had 7 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 20 mentions for Sarepta Therapeutics and 13 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.99 beat Sarepta Therapeutics' score of 0.64 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.
BioMarin Pharmaceutical received 107 more outperform votes than Sarepta Therapeutics when rated by MarketBeat users. However, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 74.70% of users gave BioMarin Pharmaceutical an outperform vote.
BioMarin Pharmaceutical has a net margin of 8.31% compared to Sarepta Therapeutics' net margin of 1.20%. BioMarin Pharmaceutical's return on equity of 5.34% beat Sarepta Therapeutics' return on equity.
Summary
BioMarin Pharmaceutical beats Sarepta Therapeutics on 10 of the 17 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
